Kaitlib Fe

Endometriosis, Low Testosterone, Osteoporosis + 16 more

Treatment

20 Active Studies for Kaitlib Fe

What is Kaitlib Fe

Norethisterone

The Generic name of this drug

Treatment Summary

Norethisterone (also known as norethindrone) is a synthetic hormone that works similarly to the hormone progesterone. It is used with or without other hormones to prevent pregnancy, regulate menstrual cycles, or to treat endometriosis and irregular menstrual cycles. It was first developed in 1951 in Mexico City and was approved for use as an oral contraceptive in 1962.

Necon

is the brand name

image of different drug pills on a surface

Kaitlib Fe Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Necon

Norethisterone

1967

347

Effectiveness

How Kaitlib Fe Affects Patients

Norethisterone is a type of hormone pill used as birth control or to treat other conditions related to hormones such as menopause and endometriosis. It has a much stronger effect than the hormone progesterone that is naturally made in the body. Norethisterone works in the pelvic area to affect the cervix and uterus, and it also stops hormones from the pituitary gland from maturing and releasing an egg. Taking norethisterone may slightly increase a person's chances of getting breast cancer, so patients should talk to their doctor about any concerns and do regular breast self-exams.

How Kaitlib Fe works in the body

Norethisterone helps prevent pregnancy by thickening cervical mucus, which makes it more difficult for sperm to get to the egg. It also weakens the lining of the uterus, making it harder for a fertilized egg to implant. Norethisterone also works in the brain to lower the levels of hormones that trigger ovulation. In menopausal women, norethisterone helps protect against endometrial cancer by blocking the growth of the endometrium in response to estrogen. Norethisterone has a low affinity for other hormone receptors, such as androgen and glucocorticoid receptors, which

When to interrupt dosage

The prescribed amount of Kaitlib Fe depends upon the determined affliction, for example Atrophic, Fracture and Hormone Replacement Therapy. The measure of dosage changes as per the administration technique (e.g. Oral or Tablet) featured in the table beneath.

Condition

Dosage

Administration

Hot flashes

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Atrophic

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Estrogen Deprivation Symptoms

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

hypoestrogenism

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Fracture

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Menopause

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Therapeutic procedure

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Birth Control

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Oral Contraceptives

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Low Testosterone

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis, Postmenopausal

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Primary Ovarian Insufficiency

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormonal Contraception

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

female castration

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormone Replacement Therapy

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Vasomotor System

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch - Transdermal, Patch, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Due to its eight contraindications, Kaitlib Fe should not be taken when confronting any of the conditions specified in the table below.

Kaitlib Fe Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thrombophilia

Do Not Combine

Vaginal Hemorrhage

Do Not Combine

Malignant Neoplasms

Do Not Combine

Benign hepatic neoplasm

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Norethisterone may interact with Pulse Frequency

There are 20 known major drug interactions with Kaitlib Fe.

Common Kaitlib Fe Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Norethisterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Norethisterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.

Clomipramine

Major

The metabolism of Clomipramine can be increased when combined with Norethisterone.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Norethisterone.

Kaitlib Fe Toxicity & Overdose Risk

The toxic dose for mice is 6g/kg and the toxic dose for women is 42mg/kg. There have been no reports of serious harm due to taking too many oral contraceptives, including in children. Signs of overdosing might include nausea and vomiting.

image of a doctor in a lab doing drug, clinical research

Kaitlib Fe Novel Uses: Which Conditions Have a Clinical Trial Featuring Kaitlib Fe?

160 active trials are presently investigating the potential of Kaitlib Fe to provide Birth Control, Atrophic Uterus relief and Low Testosterone management.

Condition

Clinical Trials

Trial Phases

Birth Control

20 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 3, Phase 4, Not Applicable, Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Low Testosterone

4 Actively Recruiting

Phase 4, Phase 2, Phase 1

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot flashes

21 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Estrogen Deprivation Symptoms

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

female castration

0 Actively Recruiting

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Hormone Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Fracture

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Menopause

0 Actively Recruiting

Kaitlib Fe Reviews: What are patients saying about Kaitlib Fe?

5

Patient Review

10/24/2017

Kaitlib Fe for Birth Control

This treatment does exactly what it's supposed to do. I don't have to worry about my period or getting pregnant, and my skin has been clearing up nicely.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kaitlib fe

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of birth control is Kaitlib Fe?

"Kaitlib FE is a combined birth control pill that contains female hormones that prevent ovulation. Aug 27, 2021"

Answered by AI

Does Kaitlib cause weight gain?

"The most common side effects were headaches, vaginal infections, nausea, menstrual cramps, breast tenderness, abdominal pain, mood changes, bacterial vaginitis, acne, irregular bleeding, and weight gain."

Answered by AI

What is Kaitlib Fe generic for?

"Kaitlib Fe is a birth control medication that is indicated for use by women to prevent pregnancy. The medication is a combination of norethindrone and ethinyl estradiol, and is taken in the form of chewable tablets. Ferrous fumarate is also included in the medication to help prevent iron deficiency anemia."

Answered by AI

Is Kaitlib Fe the same as Generess Fe?

"Lupin has been given the go-ahead by the Food and Drug Administration (FDA) to produce a generic version of Warner Chilcott's Generess Fe Chewable Tablets."

Answered by AI

Clinical Trials for Kaitlib Fe

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Have you considered Kaitlib Fe clinical trials?

We made a collection of clinical trials featuring Kaitlib Fe, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Menstrual Cycle vs. Birth Control Pills for Protein Metabolism

18 - 40
Female
Toronto, Canada

The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle. Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons. Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body. The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.

Recruiting
Has No Placebo

Goldring Center for High Performance Sport

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Waitlist Available

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Kaitlib Fe clinical trials?

We made a collection of clinical trials featuring Kaitlib Fe, we think they might fit your search criteria.
Go to Trials
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Kaitlib Fe clinical trials?

We made a collection of clinical trials featuring Kaitlib Fe, we think they might fit your search criteria.
Go to Trials